+30.4%
GSK vs MKC
-23.4%
+53.8%
-18.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MKC | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | -1.0% | -1.0% | -1.7% |
| 7D | -1.8% | -5.9% | +4.0% | -0.7% |
| 30D | -2.2% | -0.9% | -1.3% | -2.0% |
| 3M | -1.8% | +12.7% | -14.5% | -4.0% |
| 6M | -10.6% | -19.3% | +8.7% | -7.3% |
| YTD | +4.4% | -22.2% | +26.6% | +7.8% |
| 1Y | +30.4% | -23.3% | +53.8% | +37.4% |
| All | +30.4% | -23.4% | +53.8% | +37.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MKC.
Daily Out/Under-Performance
Portfolio return minus MKC return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MKC return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MKC wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling